The UK life sciences industry is built on the exchange of scientific and commercial information before formal agreements are in place. Pharmaceutical companies, biotech firms, contract research organisations, university technology transfer offices and life sciences investors routinely share drug discovery data, clinical trial protocols, regulatory filing strategies and development pipeline information with potential partners, licensees and acquirers before any licensing, co-development, asset purchase or investment agreement is executed.
NDASafe is a document preparation service, not a law firm. Our templates are legally reviewed against applicable UK law at the point of release, but every situation is different. Where significant value, unusual risk or a cross-border element is involved, take independent legal advice before you sign.
When life sciences parties need an NDA
Pre-contract disclosure in the life sciences sector spans the full drug development value chain. The most common situations requiring an NDA include:
Drug discovery and licensing discussions: A pharmaceutical or biotech company sharing compound library data, synthesis routes, target identification data and early efficacy results with a potential licensee or co-development partner before any licensing agreement is executed needs an NDA to protect that pre-contract scientific disclosure.
Biotech-pharma partnership negotiations: Early-stage biotech firms presenting their platform technology, lead compound data or preclinical results to large pharmaceutical companies in pre-deal discussions are sharing the most commercially sensitive information they hold. A mutual NDA signed before any scientific presentation or data package is shared is standard practice in these negotiations.
Clinical trial contracting with CROs: A sponsor sharing its clinical trial protocol, investigational medicinal product (IMP) data, patient population parameters, endpoint designs and safety monitoring strategy with a potential CRO before any trial conduct agreement is executed needs an NDA to prevent that scientific and regulatory data from being used for competing sponsors or disclosed to third parties.
University and academic technology transfer: University technology transfer offices presenting research discoveries, pre-patent compound data, platform technology assessments and development plans to industry partners or licensees need confidentiality protection from the first substantive discussion. An NDA protects the commercial value of the institution's IP during the evaluation phase.
Life sciences investor due diligence: A biotech company sharing its development pipeline, clinical data packages, financial projections and regulatory strategy with a venture capital or private equity investor during due diligence needs an NDA before sharing any information beyond what is already in the public domain.
CMO and CDMO supply negotiations: A pharmaceutical company sharing manufacturing process data, CMC documentation, batch record requirements and quality specifications with a contract manufacturing or development organisation before any manufacturing services agreement is executed needs an NDA to protect those trade secrets and manufacturing know-how.
What life sciences information is confidential
Life sciences confidential information spans scientific, regulatory, clinical and commercial categories. A well-drafted NDA should identify the specific types being disclosed:
- Drug discovery and compound data: compound structures, synthesis routes, compound libraries, target identification and validation data, mechanism-of-action research and early efficacy and toxicology results
- Preclinical and clinical study data: preclinical study protocols and results, clinical trial protocols, investigational brochures, IMP data, interim and final study results and safety monitoring data
- Regulatory submission data: regulatory filing strategies, IND/CTA applications, CMC (Chemistry, Manufacturing and Controls) documentation, pharmacovigilance data and MHRA or EMA submission plans
- Manufacturing and process data: manufacturing process descriptions, CMC specifications, batch record formats, quality control parameters and supply chain structures
- Pipeline and development strategy: pipeline compound lists, development stage information, planned regulatory submissions, partnering strategy and asset valuation data not yet in the public domain
- Commercial and financial data: licensing term proposals, royalty rate structures, milestone payment frameworks, commercial launch models and market access strategy
- Intellectual property data: pre-patent compound data, patent filing strategies, freedom-to-operate analysis, know-how and trade secrets not covered by filed patent applications
CDAs, MTAs and NDAs in the life sciences industry
The life sciences industry uses several overlapping agreement types to manage pre-contract information sharing.
A CDA (Confidential Disclosure Agreement) is simply the industry term for an NDA. Both documents create binding confidentiality obligations on the receiving party. The choice of term is a matter of industry convention, not legal effect.
A Material Transfer Agreement (MTA) is a different instrument: it governs the transfer of physical research materials — cell lines, compounds, biological samples — rather than information. MTAs typically include confidentiality provisions but are primarily concerned with ownership, permitted use and liability for research materials. An MTA does not replace an NDA for information disclosed alongside the materials.
A Research Collaboration Agreement (RCA) or Joint Development Agreement (JDA) is an operational agreement for an ongoing collaboration. It will typically include confidentiality provisions but also governs IP ownership, publication rights, funding and governance. An NDA or CDA is signed before the RCA or JDA is negotiated, to protect information shared during the negotiation of those more complex instruments.
In the UK and EU, a patent can be invalidated if the invention has been publicly disclosed before the patent application is filed. An NDA signed before any scientific or commercial disclosure to a potential partner or licensee creates a binding confidentiality obligation on the receiving party, helping to preserve the novelty of the invention for patent filing purposes. An NDA is not a substitute for filing a patent application — but it bridges the gap between disclosure and filing.
Life sciences NDA term length and post-termination obligations
Drug discovery and development timelines are among the longest in any commercial sector, often spanning 10 to 15 years from initial discovery to market authorisation. A standard two-year NDA term is typically inadequate for life sciences disclosure.
Life sciences NDAs should have a term of five to ten years to reflect the period over which disclosed data remains commercially sensitive. Clinical study data, regulatory strategy documents and manufacturing know-how retain commercial value well beyond the immediate transaction discussions.
Post-termination obligations are equally important. The NDA should require the receiving party to return all disclosed data, destroy any copies, delete electronic records and provide written confirmation once discussions conclude without reaching an agreement. A survival clause ensuring that confidentiality obligations survive termination for the full agreed term is standard in life sciences agreements.
NDASafe's Mutual NDA is the standard choice for biotech-pharma partnership discussions and co-development negotiations where both parties share scientific or commercial data. The One-Way NDA (disclosing party) covers university technology transfer presentations and biotech pitches to potential licensees. £29 each or £79 for all eight NDA variants — editable Word documents delivered instantly.